Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Mauricio Tohen, DR.P.H., M.D.

TitleLecturer on Psychiatry
InstitutionMcLean Hospital
DepartmentPsychiatry
AddressDivision of Mood & Anxiety Disorders
U of Texas Health Science Ctr
7703 Floyd Curls Dr
San Antonio TX 78229
Phone210/567-5329

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Lukasiewicz M, Gerard S, Besnard A, Falissard B, Perrin E, Sapin H, Tohen M, Reed C, Azorin JM. Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort. Int J Methods Psychiatr Res. 2013 Mar; 22(1):46-58.
    View in: PubMed
  2. Tohen M. Author's reply. Br J Psychiatry. 2013 Feb; 202:153-4.
    View in: PubMed
  3. Undurraga J, Vieta E, Tohen M, Colom F. Olanzapine in schizophrenia and affective disorders. Drug Saf. 2012 Dec 1; 35(12):1185-6.
    View in: PubMed
  4. Tohen M. Methodologies to avoid the enrollment of ineligible patients in clinical trials. J Clin Psychiatry. 2012 Nov; 73(11):1426-7.
    View in: PubMed
  5. Tohen M, McDonnell DP, Case M, Kanba S, Ha K, Fang YR, Katagiri H, Gomez JC. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry. 2012 Nov; 201:376-82.
    View in: PubMed
  6. Tohen M, Wang WV, Leboyer M, Jen KY. Variables as mediators or moderators in predicting relapse to any type of mood episode in a bipolar maintenance study. J Clin Psychiatry. 2012 Jul; 73(7):e913-7.
    View in: PubMed
  7. Olsen BT, Ganocy SJ, Bitter SM, Findling RL, Case M, Chang K, Tohen M, DelBello MP. Health-related quality of life as measured by the child health questionnaire in adolescents with bipolar disorder treated with olanzapine. Compr Psychiatry. 2012 Oct; 53(7):1000-5.
    View in: PubMed
  8. Katagiri H, Takita Y, Tohen M, Higuchi T, Kanba S, Takahashi M. Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder. Curr Med Res Opin. 2012 May; 28(5):701-13.
    View in: PubMed
  9. Baldessarini RJ, Tondo L, Vazquez GH, Undurraga J, Bolzani L, Yildiz A, Khalsa HM, Lai M, Lepri B, Lolich M, Maffei PM, Salvatore P, Faedda GL, Vieta E, Tohen M. Age at onset versus family history and clinical outcomes in 1,665 international bipolar-I disorder patients. World Psychiatry. 2012 Feb; 11(1):40-6.
    View in: PubMed
  10. Baldessarini RJ, Undurraga J, Vázquez GH, Tondo L, Salvatore P, Ha K, Khalsa HM, Lepri B, Ha TH, Chang JS, Tohen M, Vieta E. Predominant recurrence polarity among 928 adult international bipolar I disorder patients. Acta Psychiatr Scand. 2012 Apr; 125(4):293-302.
    View in: PubMed
  11. Kupfer DJ, Angst J, Berk M, Dickerson F, Frangou S, Frank E, Goldstein BI, Harvey A, Laghrissi-Thode F, Leboyer M, Ostacher MJ, Sibille E, Strakowski SM, Suppes T, Tohen M, Yolken RH, Young LT, Zarate CA. Advances in bipolar disorder: selected sessions from the 2011 International Conference on Bipolar Disorder. Ann N Y Acad Sci. 2011 Dec; 1242:1-25.
    View in: PubMed
  12. Katagiri H, Takita Y, Tohen M, Higuchi T, Kanba S, Takahashi M. Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study. J Affect Disord. 2012 Feb; 136(3):476-84.
    View in: PubMed
  13. Degenhardt EK, Gatz JL, Jacob J, Tohen M. Predictors of relapse or recurrence in bipolar I disorder. J Affect Disord. 2012 Feb; 136(3):733-9.
    View in: PubMed
  14. Tohen M, Khalsa HM, Salvatore P, Vieta E, Ravichandran C, Baldessarini RJ. Two-year outcomes in first-episode psychotic depression the McLean-Harvard First-Episode Project. J Affect Disord. 2012 Jan; 136(1-2):1-8.
    View in: PubMed
  15. Baldessarini RJ, Salvatore P, Khalsa HM, Imaz-Etxeberria H, Gonzalez-Pinto A, Tohen M. Episode cycles with increasing recurrences in first-episode bipolar-I disorder patients. J Affect Disord. 2012 Jan; 136(1-2):149-54.
    View in: PubMed
  16. Degenhardt EK, Tamayo JM, Jamal HH, Gatz J, Tohen M, Durell TM. Relationship between African-American or Caucasian origin and outcomes in the olanzapine treatment of acute mania: a pooled analysis of three adult studies conducted in the United States of America. Int Clin Psychopharmacol. 2011 May; 26(3):141-5.
    View in: PubMed
  17. Kemp DE, Johnson E, Wang WV, Tohen M, Calabrese JR. Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone. J Clin Psychiatry. 2011 Sep; 72(9):1236-41.
    View in: PubMed
  18. Yildiz A, Vieta E, Tohen M, Baldessarini RJ. Factors modifying drug and placebo responses in randomized trials for bipolar mania. Int J Neuropsychopharmacol. 2011 Aug; 14(7):863-75.
    View in: PubMed
  19. Berk M, Brnabic A, Dodd S, Kelin K, Tohen M, Malhi GS, Berk L, Conus P, McGorry PD. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disord. 2011 Feb; 13(1):87-98.
    View in: PubMed
  20. Severus WE, Lipkovich IA, Licht RW, Young AH, Greil W, Ketter T, Deberdt W, Tohen M. In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005. Eur Psychiatry. 2010 Dec; 25(8):443-9.
    View in: PubMed
  21. Kemp DE, Ganocy SJ, Brecher M, Carlson BX, Edwards S, Eudicone JM, Evoniuk G, Jansen W, Leon AC, Minkwitz M, Pikalov A, Stassen HH, Szegedi A, Tohen M, Van Willigenburg AP, Calabrese JR. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord. 2011 Apr; 130(1-2):171-9.
    View in: PubMed
  22. Vázquez GH, Kapczinski F, Magalhaes PV, Córdoba R, Lopez Jaramillo C, Rosa AR, Sanchez de Carmona M, Tohen M. Stigma and functioning in patients with bipolar disorder. J Affect Disord. 2011 Apr; 130(1-2):323-7.
    View in: PubMed
  23. Novick D, Reed C, Haro JM, Gonzalez-Pinto A, Perrin E, Aguado J, Tohen M. Comparison of olanzapine and risperidone in the EMBLEM Study: translation of randomized controlled trial findings into clinical practice. Int Clin Psychopharmacol. 2010 Sep; 25(5):257-63.
    View in: PubMed
  24. Salvatore P, Baldessarini RJ, Tohen M, Khalsa HM, Sanchez-Toledo JP, Zarate CA, Vieta E, Maggini C. McLean-Harvard International First-Episode Project: two-year stability of ICD-10 diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry. 2011 Feb; 72(2):183-93.
    View in: PubMed
  25. Montoya A, Tohen M, Vieta E, Casillas M, Chacón F, Polavieja P, Gilaberte I. Functioning and symptomatic outcomes in patients with bipolar I disorder in syndromal remission: a 1-year, prospective, observational cohort study. J Affect Disord. 2010 Dec; 127(1-3):50-7.
    View in: PubMed
  26. Houston JP, Ketter TA, Case M, Bowden C, Degenhardt EK, Jamal HH, Tohen M. Early symptom change and prediction of subsequent remission with olanzapine augmentation in divalproex-resistant bipolar mixed episodes. J Psychiatr Res. 2011 Feb; 45(2):169-73.
    View in: PubMed
  27. Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden CL. Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010 Jun; 18(3):143-57.
    View in: PubMed
  28. Treuer T, Tohen M. Predicting the course and outcome of bipolar disorder: a review. Eur Psychiatry. 2010 Oct; 25(6):328-33.
    View in: PubMed
  29. Baldessarini RJ, Salvatore P, Khalsa HM, Gebre-Medhin P, Imaz H, González-Pinto A, Perez J, Cruz N, Maggini C, Tohen M. Morbidity in 303 first-episode bipolar I disorder patients. Bipolar Disord. 2010 May; 12(3):264-70.
    View in: PubMed
  30. Baldessarini RJ, Salvatore P, Khalsa HM, Tohen M. Dissimilar morbidity following initial mania versus mixed-states in type-I bipolar disorder. J Affect Disord. 2010 Oct; 126(1-2):299-302.
    View in: PubMed
  31. Tohen M, Case M, Trivedi MH, Thase ME, Burke SJ, Durell TM. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry. 2010 Apr; 71(4):451-62.
    View in: PubMed
  32. Tamayo JM, Zarate CA, Vieta E, Vázquez G, Tohen M. Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2010 Jul; 13(6):813-32.
    View in: PubMed
  33. Gallo C, Tohen M. Current status and future perspectives for psychiatry/mental health research in Latin America. Int Rev Psychiatry. 2010; 22(4):382-93.
    View in: PubMed
  34. Tohen M, Sniadecki J, Sutton VK, Degenhardt EK, Karagianis JL, Sagman D, Jacobson JG. Number needed to treat or harm analyses of olanzapine for maintenance treatment of bipolar disorder. J Clin Psychopharmacol. 2009 Dec; 29(6):520-8.
    View in: PubMed
  35. Benazzi F, Berk M, Frye MA, Wang W, Barraco A, Tohen M. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. J Clin Psychiatry. 2009 Oct; 70(10):1424-31.
    View in: PubMed
  36. Houston JP, Tohen M, Degenhardt EK, Jamal HH, Liu LL, Ketter TA. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. J Clin Psychiatry. 2009 Nov; 70(11):1540-7.
    View in: PubMed
  37. Tohen M, Vieta E, Gonzalez-Pinto A, Reed C, Lin D. Baseline characteristics and outcomes in patients with first episode or multiple episodes of acute mania. J Clin Psychiatry. 2010 Mar; 71(3):255-61.
    View in: PubMed
  38. Tohen M, Frank E, Bowden CL, Colom F, Ghaemi SN, Yatham LN, Malhi GS, Calabrese JR, Nolen WA, Vieta E, Kapczinski F, Goodwin GM, Suppes T, Sachs GS, Chengappa KR, Grunze H, Mitchell PB, Kanba S, Berk M. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord. 2009 Aug; 11(5):453-73.
    View in: PubMed
  39. Tamayo JM, Sutton VK, Mattei MA, Diaz B, Jamal HH, Vieta E, Zarate CA, Fumero I, Tohen M. Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. J Clin Psychopharmacol. 2009 Aug; 29(4):358-61.
    View in: PubMed
  40. Novick D, Gonzalez-Pinto A, Haro JM, Bertsch J, Reed C, Perrin E, Tohen M. Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM study. Pharmacopsychiatry. 2009 Jul; 42(4):145-52.
    View in: PubMed
  41. Baldessarini RJ, Bolzani L, Cruz N, Jones PB, Lai M, Lepri B, Perez J, Salvatore P, Tohen M, Tondo L, Vieta E. Onset-age of bipolar disorders at six international sites. J Affect Disord. 2010 Feb; 121(1-2):143-6.
    View in: PubMed
  42. Tohen M, Vieta E. Antipsychotic agents in the treatment of bipolar mania. Bipolar Disord. 2009 Jun; 11 Suppl 2:45-54.
    View in: PubMed
  43. Vieta E, Berk M, Wang W, Colom F, Tohen M, Baldessarini RJ. Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. J Affect Disord. 2009 Dec; 119(1-3):22-7.
    View in: PubMed
  44. Carlson GA, Findling RL, Post RM, Birmaher B, Blumberg HP, Correll C, DelBello MP, Fristad M, Frazier J, Hammen C, Hinshaw SP, Kowatch R, Leibenluft E, Meyer SE, Pavuluri MN, Wagner KD, Tohen M. AACAP 2006 Research Forum--Advancing research in early-onset bipolar disorder: barriers and suggestions. J Child Adolesc Psychopharmacol. 2009 Feb; 19(1):3-12.
    View in: PubMed
  45. Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, Bauer T, Xu W, Wang W, Carlson J, Tohen M. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009 Jan; 48(1):60-70.
    View in: PubMed
  46. Salvatore P, Baldessarini RJ, Tohen M, Khalsa HM, Sanchez-Toledo JP, Zarate CA, Vieta E, Maggini C. McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry. 2009 Apr; 70(4):458-66.
    View in: PubMed
  47. Brown E, Dunner DL, McElroy SL, Keck PE, Adams DH, Degenhardt E, Tohen M, Houston JP. Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol. 2009 Jul; 12(6):773-82.
    View in: PubMed
  48. Tohen M, Sutton VK, Calabrese JR, Sachs GS, Bowden CL. Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder. J Affect Disord. 2009 Jul; 116(1-2):43-50.
    View in: PubMed
  49. Thompson PM, Bartzokis G, Hayashi KM, Klunder AD, Lu PH, Edwards N, Hong MS, Yu M, Geaga JA, Toga AW, Charles C, Perkins DO, McEvoy J, Hamer RM, Tohen M, Tollefson GD, Lieberman JA. Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cereb Cortex. 2009 May; 19(5):1107-23.
    View in: PubMed
  50. Tohen M, Vieta E, Goodwin GM, Sun B, Amsterdam JD, Banov M, Shekhar A, Aaronson ST, Bardenstein L, Grecu-Gabos I, Tochilov V, Prelipceanu D, Oliff HS, Kryzhanovskaya L, Bowden C. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry. 2008 Nov; 69(11):1776-89.
    View in: PubMed
  51. Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J Clin Psychiatry. 2008 Oct; 69(10):1580-8.
    View in: PubMed
  52. Hawkins KA, Keefe RS, Christensen BK, Addington J, Woods SW, Callahan J, Zipursky RB, Perkins DO, Tohen M, Breier A, McGlashan TH. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. Schizophr Res. 2008 Oct; 105(1-3):1-9.
    View in: PubMed
  53. Baethge C, Hennen J, Khalsa HM, Salvatore P, Tohen M, Baldessarini RJ. Sequencing of substance use and affective morbidity in 166 first-episode bipolar I disorder patients. Bipolar Disord. 2008 Sep; 10(6):738-41.
    View in: PubMed
  54. Tohen M. Clinical trials in bipolar mania: implications in study design and drug development. Arch Gen Psychiatry. 2008 Mar; 65(3):252-3.
    View in: PubMed
  55. Berk M, Ng F, Wang WV, Tohen M, Lubman DI, Vieta E, Dodd S. Going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania. J Affect Disord. 2008 Sep; 110(1-2):126-34.
    View in: PubMed
  56. Tohen M, Bowden CL, Smulevich AB, Bergstrom R, Quinlan T, Osuntokun O, Wang WV, Oliff HS, Martenyi F, Kryzhanovskaya LA, Greil W. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry. 2008 Feb; 192(2):135-43.
    View in: PubMed
  57. Karagianis J, Rosenbluth M, Tohen M, Ascher-Svanum H, Treuer T, de Lima MS, Citrome L. Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools. Curr Med Res Opin. 2007 Oct; 23(10):2551-7.
    View in: PubMed
  58. Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, Kowatch R, Wagner K, Findling R, Lin D, Robertson-Plouch C, Xu W, Dittmann RW, Biederman J. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007 Oct; 164(10):1547-56.
    View in: PubMed
  59. Hoffman RE, Woods SW, Hawkins KA, Pittman B, Tohen M, Preda A, Breier A, Glist J, Addington J, Perkins DO, McGlashan TH. Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population. Br J Psychiatry. 2007 Oct; 191:355-6.
    View in: PubMed
  60. Dubé S, Tollefson GD, Thase ME, Briggs SD, Van Campen LE, Case M, Tohen M. Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disord. 2007 Sep; 9(6):618-27.
    View in: PubMed
  61. Berk M, Malhi GS, Cahill C, Carman AC, Hadzi-Pavlovic D, Hawkins MT, Tohen M, Mitchell PB. The Bipolar Depression Rating Scale (BDRS): its development, validation and utility. Bipolar Disord. 2007 Sep; 9(6):571-9.
    View in: PubMed
  62. Montoya A, Pérez Sánchez Toledo J, Gilaberte I, González-Pinto A, Haro JM, Vieta E, Tohen M. Patterns of drug treatment for manic episode in the clinical practice. Outcomes of the Spanish sample in the EMBLEM Study. Actas Esp Psiquiatr. 2007 Sep-Oct; 35(5):315-22.
    View in: PubMed
  63. Berk M, Ng F, Wang WV, Calabrese JR, Mitchell PB, Malhi GS, Tohen M. The empirical redefinition of the psychometric criteria for remission in bipolar disorder. J Affect Disord. 2008 Feb; 106(1-2):153-8.
    View in: PubMed
  64. Khalsa HM, Salvatore P, Hennen J, Baethge C, Tohen M, Baldessarini RJ. Suicidal events and accidents in 216 first-episode bipolar I disorder patients: predictive factors. J Affect Disord. 2008 Feb; 106(1-2):179-84.
    View in: PubMed
  65. Tohen M. Collaborations between academic psychiatry and the pharmaceutical industry: a perspective from industry. Epidemiol Psichiatr Soc. 2007 Jul-Sep; 16(3):197-8.
    View in: PubMed
  66. Baldessarini RJ, Tondo L, Strombom IM, Dominguez S, Fawcett J, Licinio J, Oquendo MA, Tollefson GD, Valuck RJ, Tohen M. Ecological studies of antidepressant treatment and suicidal risks. Harv Rev Psychiatry. 2007 Jul-Aug; 15(4):133-45.
    View in: PubMed
  67. Vieta E, Panicali F, Goetz I, Reed C, Comes M, Tohen M. Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study. J Affect Disord. 2008 Feb; 106(1-2):63-72.
    View in: PubMed
  68. Niufan G, Tohen M, Qiuqing A, Fude Y, Pope E, McElroy H, Ming L, Gaohua W, Xinbao Z, Huichun L, Liang S. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. J Affect Disord. 2008 Jan; 105(1-3):101-8.
    View in: PubMed
  69. Tohen M, Calabrese J, Vieta E, Bowden C, Gonzalez-Pinto A, Lin D, Xu W, Corya S. Effect of comorbid anxiety on treatment response in bipolar depression. J Affect Disord. 2007 Dec; 104(1-3):137-46.
    View in: PubMed
  70. Salvatore P, Tohen M, Khalsa HM, Baethge C, Tondo L, Baldessarini RJ. Longitudinal research on bipolar disorders. Epidemiol Psichiatr Soc. 2007 Apr-Jun; 16(2):109-17.
    View in: PubMed
  71. Tamayo JM, Mazzotti G, Tohen M, Gattaz WF, Zapata R, Castillo JJ, Fahrer RD, González-Pinto AM, Vieta E, Azorin JM, Brown E, Brunner E, Rovner J, Bonett-Perrin E, Baker RW. Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol. J Clin Psychopharmacol. 2007 Apr; 27(2):126-34.
    View in: PubMed
  72. Goetz I, Tohen M, Reed C, Lorenzo M, Vieta E. Functional impairment in patients with mania: baseline results of the EMBLEM study. Bipolar Disord. 2007 Feb-Mar; 9(1-2):45-52.
    View in: PubMed
  73. Paul SM, Tohen M. Conflicts of interest and the credibility of psychiatric research. World Psychiatry. 2007 Feb; 6(1):33-4.
    View in: PubMed
  74. Tohen M, Bowden CL, Calabrese JR, Lin D, Forrester TD, Sachs GS, Koukopoulos A, Yatham L, Grunze H. Influence of sub-syndromal symptoms after remission from manic or mixed episodes. Br J Psychiatry. 2006 Dec; 189:515-9.
    View in: PubMed
  75. Rosso IM, Killgore WD, Cintron CM, Gruber SA, Tohen M, Yurgelun-Todd DA. Reduced amygdala volumes in first-episode bipolar disorder and correlation with cerebral white matter. Biol Psychiatry. 2007 Mar 15; 61(6):743-9.
    View in: PubMed
  76. Perlis RH, Baker RW, Zarate CA, Brown EB, Schuh LM, Jamal HH, Tohen M. Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry. 2006 Nov; 67(11):1747-53.
    View in: PubMed
  77. Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res. 2006 Sep; 86(1-3):234-43.
    View in: PubMed
  78. Houston JP, Ahl J, Meyers AL, Kaiser CJ, Tohen M, Baldessarini RJ. Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex. J Clin Psychiatry. 2006 Aug; 67(8):1246-52.
    View in: PubMed
  79. Brown EB, McElroy SL, Keck PE, Deldar A, Adams DH, Tohen M, Williamson DJ. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 2006 Jul; 67(7):1025-33.
    View in: PubMed
  80. Salvatore P, Khalsa HM, Hennen J, Tohen M, Yurgelun-Todd D, Casolari F, Depanfilis C, Maggini C, Baldessarini RJ. Psychopathology factors in first-episode affective and non-affective psychotic disorders. J Psychiatr Res. 2007 Nov; 41(9):724-36.
    View in: PubMed
  81. McEvoy JP, Johnson J, Perkins D, Lieberman JA, Hamer RM, Keefe RS, Tohen M, Glick ID, Sharma T. Insight in first-episode psychosis. Psychol Med. 2006 Oct; 36(10):1385-93.
    View in: PubMed
  82. Tohen M, Lin D. Commentary on N. Ghaemi's "Hippocratic Psychopharmacology of Bipolar Disorder" Maintenance Treatment in Bipolar Disorder. Psychiatry (Edgmont). 2006 Jun; 3(6):43-5.
    View in: PubMed
  83. Shi L, Juarez R, Hackworth J, Edgell ET, Haro JM, Vieta E, Tohen MF. Open-label olanzapine treatment in bipolar I disorder: clinical and work functional outcomes. Curr Med Res Opin. 2006 May; 22(5):961-6.
    View in: PubMed
  84. Corya SA, Perlis RH, Keck PE, Lin DY, Case MG, Williamson DJ, Tohen MF. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry. 2006 May; 67(5):798-806.
    View in: PubMed
  85. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. 2006 May; 163(5):790-9.
    View in: PubMed
  86. Williamson D, Brown E, Perlis RH, Ahl J, Baker RW, Tohen M. Clinical relevance of depressive symptom improvement in bipolar I depressed patients. J Affect Disord. 2006 Jun; 92(2-3):261-6.
    View in: PubMed
  87. Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrhino F, Green AI, Glick IB, Kahn RS, Sharma T, Tohen M, McEvoy JP, Weiden PJ, Lieberman JA. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res. 2006 Mar; 83(1):53-63.
    View in: PubMed
  88. Dando S, Tohen M. Olanzapine - relapse prevention following mania. J Psychopharmacol. 2006 Mar; 20(2 Suppl):31-8.
    View in: PubMed
  89. Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou JC, Bowden CL. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006 Feb; 163(2):247-56.
    View in: PubMed
  90. Ketter TA, Houston JP, Adams DH, Risser RC, Meyers AL, Williamson DJ, Tohen M. Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes. J Clin Psychiatry. 2006 Jan; 67(1):95-101.
    View in: PubMed
  91. Cavazzoni PA, Berg PH, Kryzhanovskaya LA, Briggs SD, Roddy TE, Tohen M, Kane JM. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J Clin Psychiatry. 2006 Jan; 67(1):107-13.
    View in: PubMed
  92. Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, Strakowski SM, Sharma T, Kahn RS, Gur RE, Tollefson GD, Lieberman JA. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005 Dec; 187:537-43.
    View in: PubMed
  93. Suppes T, Brown E, Schuh LM, Baker RW, Tohen M. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data. J Affect Disord. 2005 Dec; 89(1-3):69-77.
    View in: PubMed
  94. Strakowski SM, Johnson JL, Delbello MP, Hamer RM, Green AI, Tohen M, Lieberman JA, Glick I, Patel JK. Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophr Res. 2005 Oct 15; 78(2-3):161-9.
    View in: PubMed
  95. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Rock SL, Woolson S, Tohen M, Tollefson GD, Sanger TM, Lieberman JA. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiatry. 2006 Jan 15; 59(2):97-105.
    View in: PubMed
  96. Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW, Dell'Osso L, Evans AR, Risser R, Baker RW, Crane H, Dossenbach MR, Bowden CL. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005 Jul; 162(7):1281-90.
    View in: PubMed
  97. Keck PE, Corya SA, Altshuler LL, Ketter TA, McElroy SL, Case M, Briggs SD, Tohen M. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. J Clin Psychiatry. 2005 May; 66(5):611-6.
    View in: PubMed
  98. Baethge C, Baldessarini RJ, Khalsa HM, Hennen J, Salvatore P, Tohen M. Substance abuse in first-episode bipolar I disorder: indications for early intervention. Am J Psychiatry. 2005 May; 162(5):1008-10.
    View in: PubMed
  99. Zhu B, Tunis SL, Zhao Z, Baker RW, Lage MJ, Shi L, Tohen M. Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial. Curr Med Res Opin. 2005 Apr; 21(4):555-64.
    View in: PubMed
  100. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005 Apr; 62(4):361-70.
    View in: PubMed
  101. Chengappa KN, Hennen J, Baldessarini RJ, Kupfer DJ, Yatham LN, Gershon S, Baker RW, Tohen M. Recovery and functional outcomes following olanzapine treatment for bipolar I mania. Bipolar Disord. 2005 Feb; 7(1):68-76.
    View in: PubMed
  102. Hennen J, Perlis RH, Sachs G, Tohen M, Baldessarini RJ. Weight gain during treatment of bipolar I patients with olanzapine. J Clin Psychiatry. 2004 Dec; 65(12):1679-87.
    View in: PubMed
  103. Baker RW, Brown E, Akiskal HS, Calabrese JR, Ketter TA, Schuh LM, Trzepacz PT, Watkin JG, Tohen M. Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. Br J Psychiatry. 2004 Dec; 185:472-8.
    View in: PubMed
  104. Vieta E, Calabrese JR, Hennen J, Colom F, Martínez-Arán A, Sánchez-Moreno J, Yatham LN, Tohen M, Baldessarini RJ. Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data. J Clin Psychiatry. 2004 Oct; 65(10):1420-8.
    View in: PubMed
  105. Namjoshi MA, Risser R, Shi L, Tohen M, Breier A. Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid. J Affect Disord. 2004 Sep; 81(3):223-9.
    View in: PubMed
  106. Shi L, Schuh LM, Trzepacz PT, Huang LX, Namjoshi MA, Tohen M. Improvement of Positive and Negative Syndrome Scale cognitive score associated with olanzapine treatment of acute mania. Curr Med Res Opin. 2004 Sep; 20(9):1371-6.
    View in: PubMed
  107. Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, Sanger TM, Tollefson GD. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol. 2004 Aug; 24(4):365-73.
    View in: PubMed
  108. Perkins D, Lieberman J, Gu H, Tohen M, McEvoy J, Green A, Zipursky R, Strakowski S, Sharma T, Kahn R, Gur R, Tollefson G. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry. 2004 Jul; 185:18-24.
    View in: PubMed
  109. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry. 2004 Jun; 161(6):985-95.
    View in: PubMed
  110. Lindenmayer JP, Brown E, Baker RW, Schuh LM, Shao L, Tohen M, Ahmed S, Stauffer VL. An excitement subscale of the Positive and Negative Syndrome Scale. Schizophr Res. 2004 Jun 1; 68(2-3):331-7.
    View in: PubMed
  111. Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, Ghaemi SN, Feldman PD, Risser RC, Evans AR, Calabrese JR. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry. 2004 Apr; 184:337-45.
    View in: PubMed
  112. Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res. 2004 Feb 1; 66(2-3):125-35.
    View in: PubMed
  113. Tamayo J, Zarate C, Vieta E, Tohen M. Medications for bipolar disorders: a review of their therapeutic and pharmacological differences. Part I: from antimanics to euthymics. Actas Esp Psiquiatr. 2004 Jan; 32 Suppl 1:3-17.
    View in: PubMed
  114. Shi L, Namjoshi MA, Swindle R, Yu X, Risser R, Baker RW, Tohen M. Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clin Ther. 2004 Jan; 26(1):125-34.
    View in: PubMed
  115. Zarate CA, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry. 2004 Jan; 161(1):169-71.
    View in: PubMed
  116. Berk M, Malhi GS, Mitchell PB, Cahill CM, Carman AC, Hadzi-Pavlovic D, Hawkins MT, Tohen M. Scale matters: the need for a Bipolar Depression Rating Scale (BDRS). Acta Psychiatr Scand Suppl. 2004; (422):39-45.
    View in: PubMed
  117. Tamayo J, Zarate C, Vieta E, Tohen M. Medications for bipolar disorders: a review of their therapeutic and pharmacological differences. Part II: from sinapse to genes. Actas Esp Psiquiatr. 2004 Jan; 32 Suppl 1:18-37.
    View in: PubMed
  118. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, Lawson WB, Emsley RA, Zhang F, Baker RW, Risser RC, Namjoshi MA, Evans AR, Breier A. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003 Dec; 60(12):1218-26.
    View in: PubMed
  119. Tohen M, Zarate CA, Hennen J, Khalsa HM, Strakowski SM, Gebre-Medhin P, Salvatore P, Baldessarini RJ. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry. 2003 Dec; 160(12):2099-107.
    View in: PubMed
  120. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003 Nov; 60(11):1079-88.
    View in: PubMed
  121. Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M, McGlashan TH. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry. 2003 Aug 15; 54(4):453-64.
    View in: PubMed
  122. Baldessarini RJ, Hennen J, Wilson M, Calabrese J, Chengappa R, Keck PE, McElroy SL, Sachs G, Vieta E, Welge JA, Yatham LN, Zarate CA, Baker RW, Tohen M. Olanzapine versus placebo in acute mania: treatment responses in subgroups. J Clin Psychopharmacol. 2003 Aug; 23(4):370-6.
    View in: PubMed
  123. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003 Aug; 160(8):1396-404.
    View in: PubMed
  124. Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, Zajecka J, Schuh LM, Risser RC, Brown E, Baker RW. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003 Jul; 160(7):1263-71.
    View in: PubMed
  125. Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW, Hawkins KA, Hoffman R, Preda A, Epstein I, Addington D, Lindborg S, Marquez E, Tohen M, Breier A, McGlashan TH. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophr Res. 2003 May 1; 61(1):19-30.
    View in: PubMed
  126. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res. 2003 May 1; 61(1):7-18.
    View in: PubMed
  127. Baker RW, Tohen M, Fawcett J, Risser RC, Schuh LM, Brown E, Stauffer VL, Shao L, Tollefson GD. Acute dysphoric mania: treatment response to olanzapine versus placebo. J Clin Psychopharmacol. 2003 Apr; 23(2):132-7.
    View in: PubMed
  128. Chengappa KN, Baker RW, Shao L, Yatham LN, Tohen M, Gershon S, Kupfer DJ. Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania. Bipolar Disord. 2003 Feb; 5(1):1-5.
    View in: PubMed
  129. Baker RW, Milton DR, Stauffer VL, Gelenberg A, Tohen M. Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania. J Affect Disord. 2003 Jan; 73(1-2):147-53.
    View in: PubMed
  130. Sanger TM, Tohen M, Vieta E, Dunner DL, Bowden CL, Calabrese JR, Feldman PD, Jacobs TG, Breier A. Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. J Affect Disord. 2003 Jan; 73(1-2):155-61.
    View in: PubMed
  131. DelBello MP, Carlson GA, Tohen M, Bromet EJ, Schwiers M, Strakowski SM. Rates and predictors of developing a manic or hypomanic episode 1 to 2 years following a first hospitalization for major depression with psychotic features. J Child Adolesc Psychopharmacol. 2003; 13(2):173-85.
    View in: PubMed
  132. Russo P, Smith MW, Dirani R, Namjoshi M, Tohen M. Pharmacotherapy patterns in the treatment of bipolar disorder. Bipolar Disord. 2002 Dec; 4(6):366-77.
    View in: PubMed
  133. Gonzalez-Pinto A, Tohen M, Lalaguna B, Pérez-Heredia JL, Fernandez-Corres B, Gutierrez M, Micó JA. Treatment of bipolar I rapid cycling patients during dysphoric mania with olanzapine. J Clin Psychopharmacol. 2002 Oct; 22(5):450-4.
    View in: PubMed
  134. Shi L, Namjoshi MA, Zhang F, Gandhi G, Edgell ET, Tohen M, Breier A, Haro JM. Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. Int Clin Psychopharmacol. 2002 Sep; 17(5):227-37.
    View in: PubMed
  135. Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, Milton DR, Risser R, Gilmore JA, Breier A, Tollefson GA. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002 Jun; 159(6):1011-7.
    View in: PubMed
  136. Goldstein JM, Cohen LS, Horton NJ, Lee H, Andersen S, Tohen M, Crawford A, Tollefson G. Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Res. 2002 May 15; 110(1):27-37.
    View in: PubMed
  137. Namjoshi MA, Rajamannar G, Jacobs T, Sanger TM, Risser R, Tohen MF, Breier A, Keck PE. Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial. J Affect Disord. 2002 May; 69(1-3):109-18.
    View in: PubMed
  138. McCarley RW, Salisbury DF, Hirayasu Y, Yurgelun-Todd DA, Tohen M, Zarate C, Kikinis R, Jolesz FA, Shenton ME. Association between smaller left posterior superior temporal gyrus volume on magnetic resonance imaging and smaller left temporal P300 amplitude in first-episode schizophrenia. Arch Gen Psychiatry. 2002 Apr; 59(4):321-31.
    View in: PubMed
  139. Tohen M, Chengappa KN, Suppes T, Zarate CA, Calabrese JR, Bowden CL, Sachs GS, Kupfer DJ, Baker RW, Risser RC, Keeter EL, Feldman PD, Tollefson GD, Breier A. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002 Jan; 59(1):62-9.
    View in: PubMed
  140. Keck PE, McElroy SL, Richtand N, Tohen M. What makes a drug a primary mood stabilizer? Mol Psychiatry. 2002; 7 Suppl 1:S8-14.
    View in: PubMed
  141. Tohen M, Zhang F, Keck PE, Feldman PD, Risser RC, Tran PV, Breier A. Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. J Affect Disord. 2001 Dec; 67(1-3):133-40.
    View in: PubMed
  142. Gonzalez-Pinto A, Lalaguna B, Mosquera F, Pérez de Heredia JL, Gutierrez M, Ezcurra J, Gilaberte I, Tohen M. Use of olanzapine in dysphoric mania. J Affect Disord. 2001 Oct; 66(2-3):247-53.
    View in: PubMed
  143. Vieta E, Reinares M, Corbella B, Benabarre A, Gilaberte I, Colom F, Martínez-Arán A, Gastó C, Tohen M. Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharmacol. 2001 Oct; 21(5):469-73.
    View in: PubMed
  144. Zarate CA, Tohen M, Fletcher K. Cycling into depression from a first episode of mania: a case-comparison study. Am J Psychiatry. 2001 Sep; 158(9):1524-6.
    View in: PubMed
  145. Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, Koch M, Rizk R, Walker D, Tran P, Breier A. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001 Aug; 21(4):389-97.
    View in: PubMed
  146. Lim PZ, Tunis SL, Edell WS, Jensik SE, Tohen M. Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines. Bipolar Disord. 2001 Aug; 3(4):165-73.
    View in: PubMed
  147. Costa e Silva JA, Alvarez N, Mazzotti G, Gattaz WF, Ospina J, Larach V, Starkstein S, Oliva D, Cousins L, Tohen M, Taylor CC, Wang J, Tran PV. Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America. J Clin Psychopharmacol. 2001 Aug; 21(4):375-81.
    View in: PubMed
  148. Tohen M, Zhang F, Taylor CC, Burns P, Zarate C, Sanger T, Tollefson G. A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J Affect Disord. 2001 Jun; 65(1):85-93.
    View in: PubMed
  149. Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry. 2001 Apr; 62(4):273-81.
    View in: PubMed
  150. Frazier JA, Biederman J, Tohen M, Feldman PD, Jacobs TG, Toma V, Rater MA, Tarazi RA, Kim GS, Garfield SB, Sohma M, Gonzalez-Heydrich J, Risser RC, Nowlin ZM. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2001; 11(3):239-50.
    View in: PubMed
  151. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001 Jan; 158(1):131-4.
    View in: PubMed
  152. Chengappa KN, Tohen M, Levine J, Jacobs T, Thase ME, Sanger TM, Kupfer DJ. Response to placebo among bipolar I disorder patients experiencing their first manic episode. Bipolar Disord. 2000 Dec; 2(4):332-5.
    View in: PubMed
  153. Zarate CA, Tohen M, Land ML. First-episode schizophreniform disorder: comparisons with first-episode schizophrenia. Schizophr Res. 2000 Nov 30; 46(1):31-4.
    View in: PubMed
  154. Tohen M, Strakowski SM, Zarate C, Hennen J, Stoll AL, Suppes T, Faedda GL, Cohen BM, Gebre-Medhin P, Baldessarini RJ. The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. Biol Psychiatry. 2000 Sep 15; 48(6):467-76.
    View in: PubMed
  155. Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. Bipolar Disord. 2000 Sep; 2(3 Pt 2):261-8.
    View in: PubMed
  156. Tohen M, Bromet E, Murphy JM, Tsuang MT. Psychiatric epidemiology. Harv Rev Psychiatry. 2000 Sep; 8(3):111-25.
    View in: PubMed
  157. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry. 2000 Sep; 57(9):841-9.
    View in: PubMed
  158. Green AI, Tohen M, Patel JK, Banov M, DuRand C, Berman I, Chang H, Zarate C, Posener J, Lee H, Dawson R, Richards C, Cole JO, Schatzberg AF. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry. 2000 Jun; 157(6):982-6.
    View in: PubMed
  159. Baldessarini RJ, Tohen M, Tondo L. Maintenance treatment in bipolar disorder. Arch Gen Psychiatry. 2000 May; 57(5):490-2.
    View in: PubMed
  160. Tohen M, Hennen J, Zarate CM, Baldessarini RJ, Strakowski SM, Stoll AL, Faedda GL, Suppes T, Gebre-Medhin P, Cohen BM. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry. 2000 Feb; 157(2):220-8.
    View in: PubMed
  161. Zarate CA, Tohen M, Land M, Cavanagh S. Functional impairment and cognition in bipolar disorder. Psychiatr Q. 2000; 71(4):309-29.
    View in: PubMed
  162. Zarate CA, Tohen M. Antipsychotic drug treatment in first-episode mania: a 6-month longitudinal study. J Clin Psychiatry. 2000 Jan; 61(1):33-8.
    View in: PubMed
  163. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 1999 May; 156(5):702-9.
    View in: PubMed
  164. Zarate CA, Tohen M, Narendran R, Tomassini EC, McDonald J, Sederer M, Madrid AR. The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study. J Clin Psychiatry. 1999 Apr; 60(4):232-6.
    View in: PubMed
  165. Tohen M, Grundy S. Management of acute mania. J Clin Psychiatry. 1999; 60 Suppl 5:31-4; discussion 35-6.
    View in: PubMed
  166. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C, Tollefson GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry. 1999 Jan; 156(1):79-87.
    View in: PubMed
  167. Hirayasu Y, Shenton ME, Salisbury DF, Dickey CC, Fischer IA, Mazzoni P, Kisler T, Arakaki H, Kwon JS, Anderson JE, Yurgelun-Todd D, Tohen M, McCarley RW. Lower left temporal lobe MRI volumes in patients with first-episode schizophrenia compared with psychotic patients with first-episode affective disorder and normal subjects. Am J Psychiatry. 1998 Oct; 155(10):1384-91.
    View in: PubMed
  168. Kirkpatrick B, Ram R, Amador XF, Buchanan RW, McGlashan T, Tohen M, Bromet E. Summer birth and the deficit syndrome of schizophrenia. Am J Psychiatry. 1998 Sep; 155(9):1221-6.
    View in: PubMed
  169. Tohen M, Greenfield SF, Weiss RD, Zarate CA, Vagge LM. The effect of comorbid substance use disorders on the course of bipolar disorder: a review. Harv Rev Psychiatry. 1998 Sep-Oct; 6(3):133-41.
    View in: PubMed
  170. Kinney DK, Yurgelun-Todd DA, Tohen M, Tramer S. Pre- and perinatal complications and risk for bipolar disorder: a retrospective study. J Affect Disord. 1998 Sep; 50(2-3):117-24.
    View in: PubMed
  171. Tondo L, Baldessarini RJ, Hennen J, Floris G, Silvetti F, Tohen M. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry. 1998 Aug; 59(8):405-14.
    View in: PubMed
  172. Weiss RD, Greenfield SF, Najavits LM, Soto JA, Wyner D, Tohen M, Griffin ML. Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psychiatry. 1998 Apr; 59(4):172-4.
    View in: PubMed
  173. Kwon JS, Shenton ME, Hirayasu Y, Salisbury DF, Fischer IA, Dickey CC, Yurgelun-Todd D, Tohen M, Kikinis R, Jolesz FA, McCarley RW. MRI study of cavum septi pellucidi in schizophrenia, affective disorder, and schizotypal personality disorder. Am J Psychiatry. 1998 Apr; 155(4):509-15.
    View in: PubMed
  174. Salisbury DF, Shenton ME, Sherwood AR, Fischer IA, Yurgelun-Todd DA, Tohen M, McCarley RW. First-episode schizophrenic psychosis differs from first-episode affective psychosis and controls in P300 amplitude over left temporal lobe. Arch Gen Psychiatry. 1998 Feb; 55(2):173-80.
    View in: PubMed
  175. Zarate CA, Narendran R, Tohen M, Greaney JJ, Berman A, Pike S, Madrid A. Clinical predictors of acute response with olanzapine in psychotic mood disorders. J Clin Psychiatry. 1998 Jan; 59(1):24-8.
    View in: PubMed
  176. Stormberg D, Ronningstam E, Gunderson J, Tohen M. Brief communication: pathological narcissism in bipolar disorder patients. J Pers Disord. 1998; 12(2):179-85.
    View in: PubMed
  177. Tohen M, Zarate CA. Antipsychotic agents and bipolar disorder. J Clin Psychiatry. 1998; 59 Suppl 1:38-48; discussion 49.
    View in: PubMed
  178. Zarate CA, Tohen M, Zarate SB. Thyroid function tests in first-episode bipolar disorder manic and mixed types. Biol Psychiatry. 1997 Aug 15; 42(4):302-4.
    View in: PubMed
  179. Zarate CA, Baldessarini RJ, Siegel AJ, Nakamura A, McDonald J, Muir-Hutchinson LA, Cherkerzian T, Tohen M. Risperidone in the elderly: a pharmacoepidemiologic study. J Clin Psychiatry. 1997 Jul; 58(7):311-7.
    View in: PubMed
  180. Revicki DA, Tohen M, Gyulai L, Thompson C, Pike S, Davis-Vogel A, Zarate C. Telephone versus in-person clinical and health status assessment interviews in patients with bipolar disorder. Harv Rev Psychiatry. 1997 Jul-Aug; 5(2):75-81.
    View in: PubMed
  181. Gardner DM, Baldessarini RJ, Benzo J, Zarate CA, Tohen M. Switching between clozapine and risperidone treatment. Can J Psychiatry. 1997 May; 42(4):430-1.
    View in: PubMed
  182. Zarate CA, Tohen M, Baraibar G. Combined valproate or carbamazepine and electroconvulsive therapy. Ann Clin Psychiatry. 1997 Mar; 9(1):19-25.
    View in: PubMed
  183. Zarate CA, Tohen M, Baraibar G, Zarate SB, Baldessarini RJ. Shifts in hospital diagnostic frequencies: bipolar disorder subtypes, 1981-1993. J Affect Disord. 1997 Mar; 43(1):79-84.
    View in: PubMed
  184. Popli AP, Hegarty JD, Siegel AJ, Kando JC, Tohen M. Transfer of psychiatric inpatients to a general hospital due to adverse drug reactions. Psychosomatics. 1997 Jan-Feb; 38(1):35-7.
    View in: PubMed
  185. Lyons MJ, Tyrer P, Gunderson J, Tohen M. Heuristic models of comorbidity of axis I and axis II disorders. J Pers Disord. 1997; 11(3):260-9.
    View in: PubMed
  186. Tyrer P, Gunderson J, Lyons M, Tohen M. Extent of comorbidity between mental state and personality disorders. J Pers Disord. 1997; 11(3):242-59.
    View in: PubMed
  187. Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry. 1997 Jan; 54(1):49-55.
    View in: PubMed
  188. Strakowski SM, Flaum M, Amador X, Bracha HS, Pandurangi AK, Robinson D, Tohen M. Racial differences in the diagnosis of psychosis. Schizophr Res. 1996 Aug 23; 21(2):117-24.
    View in: PubMed
  189. Tohen M, Zarate CA, Centorrino F, Hegarty JI, Froeschl M, Zarate SB. Risperidone in the treatment of mania. J Clin Psychiatry. 1996 Jun; 57(6):249-53.
    View in: PubMed
  190. Kando JC, Tohen M, Castillo J, Zarate CA. The use of valproate in an elderly population with affective symptoms. J Clin Psychiatry. 1996 Jun; 57(6):238-40.
    View in: PubMed
  191. Kirkpatrick B, Amador XF, Flaum M, Yale SA, Gorman JM, Carpenter WT, Tohen M, McGlashan T. The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse. Schizophr Res. 1996 May; 20(1-2):69-77.
    View in: PubMed
  192. Kirkpatrick B, Amador XF, Yale SA, Bustillo JR, Buchanan RW, Tohen M. The deficit syndrome in the DSM-IV Field Trial. Part II. Depressive episodes and persecutory beliefs. Schizophr Res. 1996 May; 20(1-2):79-90.
    View in: PubMed
  193. Pillay SS, Stoll AL, Weiss MK, Tohen M, Zarate CA, Banov MD, Cole JO. EEG abnormalities before clozapine therapy predict a good clinical response to clozapine. Ann Clin Psychiatry. 1996 Mar; 8(1):1-5.
    View in: PubMed
  194. Zarate CA, Kando JC, Tohen M, Weiss MK, Cole JO. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry. 1996 Feb; 57(2):67-71.
    View in: PubMed
  195. Zarate CA, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry. 1995 Sep; 56(9):411-7.
    View in: PubMed
  196. Greenfield SF, Weiss RD, Tohen M. Substance abuse and the chronically mentally ill: a description of dual diagnosis treatment services in a psychiatric hospital. Community Ment Health J. 1995 Jun; 31(3):265-77.
    View in: PubMed
  197. Zarate CA, Tohen M, Baraibar G, Kando JC, Mirin J. Prescribing trends of antidepressants in bipolar depression. J Clin Psychiatry. 1995 Jun; 56(6):260-4.
    View in: PubMed
  198. Popli AP, Kando JC, Pillay SS, Tohen M, Cole JO. Occurrence of seizures related to psychotropic medication among psychiatric inpatients. Psychiatr Serv. 1995 May; 46(5):486-8.
    View in: PubMed
  199. Renshaw PF, Yurgelun-Todd DA, Tohen M, Gruber S, Cohen BM. Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis. Am J Psychiatry. 1995 Mar; 152(3):444-6.
    View in: PubMed
  200. Tohen M, Castillo J, Baldessarini RJ, Zarate C, Kando JC. Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiatry. 1995 Mar; 152(3):413-8.
    View in: PubMed
  201. Zarate CA, Tohen M, Banov MD, Weiss MK, Cole JO. Is clozapine a mood stabilizer? J Clin Psychiatry. 1995 Mar; 56(3):108-12.
    View in: PubMed
  202. Strakowski SM, Tohen M, Flaum M, Amador X. Substance abuse in psychotic disorders: associations with affective syndromes. DSM-IV Field Trial Work Group. Schizophr Res. 1994 Dec; 14(1):73-81.
    View in: PubMed
  203. Stoll AL, Mayer PV, Kolbrener M, Goldstein E, Suplit B, Lucier J, Cohen BM, Tohen M. Antidepressant-associated mania: a controlled comparison with spontaneous mania. Am J Psychiatry. 1994 Nov; 151(11):1642-5.
    View in: PubMed
  204. Stoll AL, Banov M, Kolbrener M, Mayer PV, Tohen M, Strakowski SM, Castillo J, Suppes T, Cohen BM. Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders. J Clin Psychopharmacol. 1994 Oct; 14(5):311-3.
    View in: PubMed
  205. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994 Oct; 151(10):1409-16.
    View in: PubMed
  206. Sachs GS, Lafer B, Stoll AL, Banov M, Thibault AB, Tohen M, Rosenbaum JF. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry. 1994 Sep; 55(9):391-3.
    View in: PubMed
  207. Banov MD, Zarate CA, Tohen M, Scialabba D, Wines JD, Kolbrener M, Kim JW, Cole JO. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry. 1994 Jul; 55(7):295-300.
    View in: PubMed
  208. Tohen M. Applications of pharmacoepidemiology in psychiatry. Harv Rev Psychiatry. 1994 Jul-Aug; 2(2):117-8.
    View in: PubMed
  209. Greenfield SF, Strakowski SM, Tohen M, Batson SC, Kolbrener ML. Childhood abuse in first-episode psychosis. Br J Psychiatry. 1994 Jun; 164(6):831-4.
    View in: PubMed
  210. Kando JC, Tohen M, Castillo J, Centorrino F. Concurrent use of clozapine and valproate in affective and psychotic disorders. J Clin Psychiatry. 1994 Jun; 55(6):255-7.
    View in: PubMed
  211. Shulman KI, Tohen M. Unipolar mania reconsidered: evidence from an elderly cohort. Br J Psychiatry. 1994 Apr; 164(4):547-9.
    View in: PubMed
  212. Tohen M, Castillo J, Pope HG, Herbstein J. Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders. J Clin Psychopharmacol. 1994 Feb; 14(1):67-70.
    View in: PubMed
  213. Tohen M, Shulman KI, Satlin A. First-episode mania in late life. Am J Psychiatry. 1994 Jan; 151(1):130-2.
    View in: PubMed
  214. Weiss MK, Tohen M, Zarate C, Iversen A. Diagnosis and management of bipolar II disorder. Compr Ther. 1994; 20(2):121-4.
    View in: PubMed
  215. Banov MD, Tohen M, Friedberg J. High risk of eosinophilia in women treated with clozapine. J Clin Psychiatry. 1993 Dec; 54(12):466-9.
    View in: PubMed
  216. Stoll AL, Tohen M, Baldessarini RJ, Goodwin DC, Stein S, Katz S, Geenens D, Swinson RP, Goethe JW, McGlashan T. Shifts in diagnostic frequencies of schizophrenia and major affective disorders at six North American psychiatric hospitals, 1972-1988. Am J Psychiatry. 1993 Nov; 150(11):1668-73.
    View in: PubMed
  217. Suppes T, Baldessarini RJ, Faedda GL, Tondo L, Tohen M. Discontinuation of maintenance treatment in bipolar disorder: risks and implications. Harv Rev Psychiatry. 1993 Sep-Oct; 1(3):131-44.
    View in: PubMed
  218. Strakowski SM, Stoll AL, Tohen M, Faedda GL, Goodwin DC. The Tridimensional Personality Questionnaire as a predictor of six-month outcome in first episode mania. Psychiatry Res. 1993 Jul; 48(1):1-8.
    View in: PubMed
  219. Faedda GL, Tondo L, Baldessarini RJ, Suppes T, Tohen M. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry. 1993 Jun; 50(6):448-55.
    View in: PubMed
  220. Strakowski SM, Tohen M, Stoll AL, Faedda GL, Mayer PV, Kolbrener ML, Goodwin DC. Comorbidity in psychosis at first hospitalization. Am J Psychiatry. 1993 May; 150(5):752-7.
    View in: PubMed
  221. Strakowski SM, Wilson DR, Tohen M, Woods BT, Douglass AW, Stoll AL. Structural brain abnormalities in first-episode mania. Biol Psychiatry. 1993 Apr 15-May 1; 33(8-9):602-9.
    View in: PubMed
  222. Strakowski SM, Woods BT, Tohen M, Wilson DR, Douglass AW, Stoll AL. MRI subcortical signal hyperintensities in mania at first hospitalization. Biol Psychiatry. 1993 Feb 1; 33(3):204-6.
    View in: PubMed
  223. Tohen M, Tsuang MT, Goodwin DC. Prediction of outcome in mania by mood-congruent or mood-incongruent psychotic features. Am J Psychiatry. 1992 Nov; 149(11):1580-4.
    View in: PubMed
  224. Stoll AL, Tohen M, Baldessarini RJ. Increasing frequency of the diagnosis of obsessive-compulsive disorder. Am J Psychiatry. 1992 May; 149(5):638-40.
    View in: PubMed
  225. Strakowski SM, Tohen M, Stoll AL, Faedda GL, Goodwin DC. Comorbidity in mania at first hospitalization. Am J Psychiatry. 1992 Apr; 149(4):554-6.
    View in: PubMed
  226. Shulman KI, Tohen M, Satlin A, Mallya G, Kalunian D. Mania compared with unipolar depression in old age. Am J Psychiatry. 1992 Mar; 149(3):341-5.
    View in: PubMed
  227. Strakowski SM, Faedda GL, Tohen M, Goodwin DC, Stoll AL. Possible affective-state dependence of the Tridimensional Personality Questionnaire in first-episode psychosis. Psychiatry Res. 1992 Mar; 41(3):215-26.
    View in: PubMed
  228. Tohen M, Stoll AL, Strakowski SM, Faedda GL, Mayer PV, Goodwin DC, Kolbrener ML, Madigan AM. The McLean First-Episode Psychosis Project: six-month recovery and recurrence outcome. Schizophr Bull. 1992; 18(2):273-82.
    View in: PubMed
  229. Tohen M, Castillo J, Cole JO, Miller MG, de los Heros R, Farrer RJ. Thrombocytopenia associated with carbamazepine: a case series. J Clin Psychiatry. 1991 Dec; 52(12):496-8.
    View in: PubMed
  230. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry. 1991 Dec; 48(12):1082-8.
    View in: PubMed
  231. Faedda GL, Baldessarini RJ, Tohen M, Strakowski SM, Waternaux C. Episode sequence in bipolar disorder and response to lithium treatment. Am J Psychiatry. 1991 Sep; 148(9):1237-9.
    View in: PubMed
  232. Strakowski SM, Hudson JI, Keck PE, Wilson DR, Frankenburg FR, Alpert JE, Teschke GC, Tohen M. Four cases of obstructive sleep apnea associated with treatment-resistant mania. J Clin Psychiatry. 1991 Apr; 52(4):156-8.
    View in: PubMed
  233. Tohen M, Waternaux CM, Tsuang MT. Outcome in Mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry. 1990 Dec; 47(12):1106-11.
    View in: PubMed
  234. Tohen M, Waternaux CM, Tsuang MT, Hunt AT. Four-year follow-up of twenty-four first-episode manic patients. J Affect Disord. 1990 Jun; 19(2):79-86.
    View in: PubMed
  235. Hudson JI, Lipinski JF, Frankenburg FR, Tohen M, Kupfer DJ. Effects of lithium on sleep in mania. Biol Psychiatry. 1989 Mar 1; 25(5):665-8.
    View in: PubMed
  236. Dion GL, Tohen M, Anthony WA, Waternaux CS. Symptoms and functioning of patients with bipolar disorder six months after hospitalization. Hosp Community Psychiatry. 1988 Jun; 39(6):652-7.
    View in: PubMed
  237. Frankenburg FR, Tohen M, Cohen BM, Lipinski JF. Long-term response to carbamazepine: a retrospective study. J Clin Psychopharmacol. 1988 Apr; 8(2):130-2.
    View in: PubMed
  238. Baldessarini RJ, Tohen M. Is there a long-term protective effect of mood-altering agents in unipolar depressive disorder? Psychopharmacol Ser. 1988; 5:130-9.
    View in: PubMed
  239. Pope HG, Jonas JM, Hudson JI, Cohen BM, Tohen M. An empirical study of psychosis in borderline personality disorder. Am J Psychiatry. 1985 Nov; 142(11):1285-90.
    View in: PubMed
  240. Lipinski JF, Cohen BM, Frankenburg F, Tohen M, Waternaux C, Altesman R, Jones B, Harris P. Open trial of S-adenosylmethionine for treatment of depression. Am J Psychiatry. 1984 Mar; 141(3):448-50.
    View in: PubMed
  241. Tohen M, Frankenburg FR. Preparation for the certification examination. Can J Psychiatry. 1983 Oct; 28(6):471-4.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Tohen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (406) concept(s)
_
Co-Authors
See all (49) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_